Family Management Corp increased its stake in Pfizer Inc. (NYSE:PFE) by 49.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,507 shares of the biopharmaceutical company’s stock after buying an additional 6,820 shares during the period. Family Management Corp’s holdings in Pfizer were worth $744,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in the stock. Mutual Advisors LLC grew its holdings in Pfizer by 6.4% in the second quarter. Mutual Advisors LLC now owns 45,326 shares of the biopharmaceutical company’s stock worth $1,644,000 after purchasing an additional 2,743 shares during the period. Putnam Investments LLC grew its holdings in Pfizer by 9.3% in the second quarter. Putnam Investments LLC now owns 6,371,663 shares of the biopharmaceutical company’s stock worth $231,164,000 after purchasing an additional 541,774 shares during the period. Cozad Asset Management Inc. purchased a new stake in Pfizer in the second quarter worth about $2,996,000. Moneta Group Investment Advisors LLC grew its holdings in Pfizer by 86.6% in the second quarter. Moneta Group Investment Advisors LLC now owns 130,137 shares of the biopharmaceutical company’s stock worth $2,849,000 after purchasing an additional 60,379 shares during the period. Finally, OLD Mutual Customised Solutions Proprietary Ltd. grew its holdings in Pfizer by 7.5% in the second quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 128,530 shares of the biopharmaceutical company’s stock worth $4,663,000 after purchasing an additional 9,000 shares during the period. 69.42% of the stock is owned by institutional investors.
In related news, major shareholder Pfizer Inc bought 55,556 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The shares were bought at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the acquisition, the insider now owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.03. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The company had revenue of $13.30 billion for the quarter, compared to analysts’ expectations of $13.53 billion. During the same quarter last year, the company posted $0.67 earnings per share. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 3 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Monday, December 3rd. Investors of record on Friday, November 9th were issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 2.96%. The ex-dividend date of this dividend was Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.
PFE has been the topic of a number of recent research reports. Cantor Fitzgerald restated a “buy” rating and issued a $53.00 price objective on shares of Pfizer in a report on Wednesday, October 17th. Barclays set a $40.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Friday, October 19th. Morgan Stanley set a $45.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Thursday, September 13th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, October 30th. Finally, Credit Suisse Group set a $40.00 price target on shares of Pfizer and gave the company a “hold” rating in a report on Sunday, October 14th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $43.27.
ILLEGAL ACTIVITY WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.com-unik.info/2018/12/04/family-management-corp-grows-position-in-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: What is the 52-week high/low?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.